Drug Regulatory Science in EU and Its Enlightenment to China

摘要/Abstract

摘要： Objective To analyze the current situation of research and application of drug regulatory science in EU, and provide suggestions for policy-making of drug regulatory in China. Methods The policy guidelines issued by European Medicines Agency (EMA) and domestic and foreign literature were retrieved to summarize how to carry out drug regulation science in Europe. Results and Conclusion A strategic plan was formulated by the EMA for the implementation of drug regulatory science, and the construction of academic system and discourse system of regulatory science were improved, which played a role in promoting the progress of European drug regulatory science. It is suggested that a phased strategic plan of regulatory science should be established to clarify strategic objectives and main tasks in China as soon as possible. Besides, the construction of discipline system and discourse system should be strengthened to realize the scientific supervision of drugs.

关键词: EU, EMA, drug regulatory science, enlightenment

Abstract: Objective To analyze the current situation of research and application of drug regulatory science in EU, and provide suggestions for policy-making of drug regulatory in China. Methods The policy guidelines issued by European Medicines Agency (EMA) and domestic and foreign literature were retrieved to summarize how to carry out drug regulation science in Europe. Results and Conclusion A strategic plan was formulated by the EMA for the implementation of drug regulatory science, and the construction of academic system and discourse system of regulatory science were improved, which played a role in promoting the progress of European drug regulatory science. It is suggested that a phased strategic plan of regulatory science should be established to clarify strategic objectives and main tasks in China as soon as possible. Besides, the construction of discipline system and discourse system should be strengthened to realize the scientific supervision of drugs.

Key words: EU, EMA, drug regulatory science, enlightenment

Li Yanying , Huang Zhe, Lian Guiyu. Drug Regulatory Science in EU and Its Enlightenment to China[J]. 亚洲社会药学, 2022, 17(2): 115-119.

Li Yanying , Huang Zhe, Lian Guiyu. Drug Regulatory Science in EU and Its Enlightenment to China[J]. Asian Journal of Social Pharmacy, 2022, 17(2): 115-119.

[1]	Li Siwen , Yang Yue. The Impact of Generic Drug Consistency Evaluation Policy on Pharmaceutical Enterprises [J]. 亚洲社会药学, 2022, 17(2): 104-114.
[2]	Shen Manzhu, Zeng Yingying, Yuan Hongmei, Fu Shuyong. The Development of DTP Pharmacy and Its Impact on Pharmaceutical Enterprises [J]. 亚洲社会药学, 2022, 17(2): 159-166.
[3]	Wang Dan, Liu Chunping, Zhang Fang, Gao jinglei. A systematic Review of the Safety and Effectiveness of Epidural Analgesia for Labor Analgesia [J]. 亚洲社会药学, 2022, 17(2): 186-197.
[4]	Yang Dianzheng, Xu Wenxiu, Qi Yun, Yang Yue. Strategic Research on Pharmaceutical Enterprises’Participation in National Drug Centralized Procurement[J]. 亚洲社会药学, 2022, 17(1): 15-22.
[5]	Li Yunlong, Ning Bowen, Yuan Hongmei. Suggestions on Foreign Pharmaceutical Enterprises Dealing with China’s Drug Centralized Procurement – Taking the First Batch of Implementation Results as an Example[J]. 亚洲社会药学, 2022, 17(1): 23-33.
[6]	An Lianyu, Liu Linchuan, Wang Shuling. Design of Pharmaceutical Care Process for Retail Pharmacies Based on Pareto Analysis [J]. 亚洲社会药学, 2022, 17(1): 50-60.
[7]	Xiang You, Tian Lijuan. Policy Comparison between Shenzhen GPO and Guangdong Medicine Exchange Center[J]. 亚洲社会药学, 2021, 16(4): 290-294.
[8]	Wang Yuzhuo, Wang Su, Chen Yuwen. Research on the Relationship between Salary Incentives for R&D Personnel and R&D Investment in China’s Pharmaceutical Industry[J]. 亚洲社会药学, 2021, 16(4): 295-304.
[9]	Kudireti·shataer , Chen Yuwen. Research on the Relationship between the Profitability and R&D Investment of Enterprises of Different Scales in China’s Pharmaceutical Industry[J]. 亚洲社会药学, 2021, 16(4): 305-319.
[10]	Huang Yufeng, Ning Bowen, Yuan Hongmei. Identification of Technology Catch-up Path from the Perspective of Technology Leapfrogging[J]. 亚洲社会药学, 2021, 16(4): 320-328.
[11]	Wang Xinyue, Lin Xiangpeng, Sun Xiaohua, Wang Shuling. Selection Method of Production Enterprises by Large Pharmaceutical Commercial Companies Based on AHP[J]. 亚洲社会药学, 2021, 16(4): 334-342.
[12]	Ma Jia, Li Xiaoqi, Raela·Abduhilil, Sun Lihua. Management of Orphan Drug Reimbursement Abroad and Its Enlightenment to China[J]. 亚洲社会药学, 2021, 16(4): 352-357.
[13]	Yang Lingling, Xu Fengxiang. EU Real-World Evidence Supports New Drug Research and Development Decisions and Its Implications for China[J]. 亚洲社会药学, 2021, 16(3): 197-202.
[14]	Lan Yipeng, Huang Zhe. Real-World Evidence Supporting New Drug Review and Approval in European Union and Its Enlightenment to China[J]. 亚洲社会药学, 2021, 16(3): 203-208.
[15]	Yu Zhongyi, Xu Fengxiang. The Enlightenment of EU Real-World Evidence Supporting the Inclusion of Rare Disease Drugs in Medical Insurance Decisions to China[J]. 亚洲社会药学, 2021, 16(3): 209-213.

亚洲社会药学